Truist Securities Maintains Buy on Disc Medicine, Raises Price Target to $115

Truist Securities analyst Danielle Brill has reiterated a Buy rating on Disc Medicine (NASDAQ: IRON) and increased the price target from $83 to $115. This adjustment reflects a positive outlook for the company's performance in the market.